Clinical Trial Update: T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating trastuzumab deruxtecan (T-DXd) with or without neratinib in HER2-positive breast cancer patients with brain metastases; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Cancer with Brain Metastases

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• Nerlynx (neratinib)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING